2021 | Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial | Suzuki, Kenshi; Min, Chang-Ki; Kim, Kihyun; Lee, Je-Jung; Shibayama, Hirohiko; Ko, Po-Shen; SHANG-YI HUANG ; Li, Sin-Syue; Ding, Bifeng; Khurana, Monica; Iida, Shinsuke | International journal of hematology | 4 | 5 | |
2022 | Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis | Sunami, Kazutaka; Ikeda, Takashi; SHANG-YI HUANG ; Wang, Ming-Chung; Koh, Youngil; Min, Chang Ki; Yeh, Su-Peng; Matsumoto, Morio; Uchiyama, Michihiro; Iyama, Satoshi; Shimazaki, Chihiro; Lee, Jae Hoon; Kim, Kihyun; Kaneko, Hitomi; Kim, Jin Seok; Lin, Tung-Liang; Campana, Frank; Tada, Keisuke; Iida, Shinsuke; Suzuki, Kenshi | Clinical lymphoma, myeloma & leukemia | 0 | 0 | |